Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example

被引:6
|
作者
Dalhoff, Axel [1 ]
Bowker, Karen [2 ]
MacGowan, Alasdair [2 ]
机构
[1] Christian Albrechts Univ Kiel, Inst Infect Med, Brunswiker Str 4, D-24105 Kiel, Germany
[2] North Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Southmead Hosp, Infect Sci, Bristol BS10 5NB, Avon, England
关键词
Pharmacodynamic model; Infection; Washout of bacteria; Immunocompetence; Inoculum preparation; BETA-LACTAM ANTIBIOTICS; INVITRO MODEL; ADSORPTION; SURFACE; BACTERIA; ADHESION; CULTURE; SERUM;
D O I
10.1016/j.ijantimicag.2019.09.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Use of pharmacodynamic in vitro models provides more clinically relevant information about the activities of antibiotics than static endpoints. Several models are used to simulate pharmacokinetics by dilution of the medium. It is discussed whether this procedure would result in a washout of bacteria, particularly if profiles with a short half-life are simulated. Methods have been developed to minimise the washout of bacteria. Bacteria are retained in the system either by centrifugation and resuspension, use of filters, a capillary unit, dialysis tubing or mathematical correction, versus systems with an unprotected outflow allowing a continuous washout of bacteria. None of these eight models has been directly compared with another. Therefore, an interlaboratory study was performed to address the question of whether or not washout matters. All laboratories used identical batches of media, bacteria, antibiotics and simulated pharmacokinetic profiles with a short or long half-life. Values of area under the bacterial kill-time curve (AUBKC), single-point kill rate and time to 3-log(10) reduction of inoculum were calculated. These parameters did not differ significantly between the models. Differences were noted if the inoculum was prepared from the early logarithmic growth phase compared with the late logarithmic or stationary growth phase, resulting either in a pronounced or reduced antibacterial activity. Thus, preparation of inocula affects the results generated, whereas washout of bacteria has apparently a negligible impact on antibacterial activities. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection
    MacGowan, AP
    Bowker, KE
    Wootton, M
    Holt, HA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) : 1560 - 1564
  • [2] Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model
    Esposito, S
    Noviello, S
    Ianniello, F
    [J]. JOURNAL OF CHEMOTHERAPY, 2000, 12 (06) : 475 - 481
  • [3] Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms
    Vandevelde, Nathalie M.
    Tulkens, Paul M.
    Muccioli, Giulio G.
    Van Bambeke, Francois
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (06) : 1713 - 1726
  • [4] In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae
    Fukuda, Yoshiko
    Takahata, Masahiro
    Sugiura, Yoko
    Shinmura, Yuko
    Nomura, Nobuhiko
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (02) : 163 - 167
  • [5] Moxifloxacin:: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae
    Reinert, RR
    Schlaeger, JJ
    Lütticken, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) : 803 - 806
  • [6] Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures
    Schaumann, R
    Goldstein, EJC
    Forberg, J
    Rodloff, AC
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (08) : 749 - 753
  • [7] Activity of moxifloxacin against Streptococcus pneumoniae using a murine lung-infection model
    Bast, DJ
    Yue, M
    Salim, K
    Davidson, RJ
    Mandell, LA
    Low, DE
    de Azavedo, JCS
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 : 38 - 38
  • [8] Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model
    Singh, Renu
    Ledesma, Kimberly R.
    Chang, Kai-Tai
    Hou, Jing-Guo
    Prince, Randall A.
    Tam, Vincent H.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (03) : 556 - 562
  • [9] In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV
    Garrison, MW
    Schimmels, JA
    Madaras-Kelly, KJ
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 47 (04) : 587 - 593
  • [10] Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model
    Allen, GP
    Kaatz, GW
    Rybak, MJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) : 2606 - 2614